Interferon alfa-2a
Roferon-A (interferon alfa-2a) is a protein pharmaceutical. Interferon alfa-2a was first approved as Roferon-a on 1986-06-04. It is used to treat brain neoplasms, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, and essential thrombocythemia amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 1 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Show 12 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0145 | Injection, pegylated interferon alfa-2a, 180 mcg per ml |
Clinical
Clinical Trials
423 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | — | K75.9 | 1 | 11 | 23 | 23 | 16 | 73 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 11 | 23 | 23 | 16 | 73 |
| Hepatitis c | D006526 | — | B19.2 | 1 | 6 | 13 | 15 | 13 | 48 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 9 | 11 | 12 | 15 | 48 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 5 | 9 | 11 | 2 | 26 |
| Hepatitis b | D006509 | — | — | — | 5 | 10 | 10 | 2 | 25 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 2 | 7 | 6 | 2 | 16 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 4 | 4 | 1 | — | 10 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | — | 1 | 1 | 4 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 4 | 2 | — | 2 | 7 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 2 | — | — | 5 |
| Chronic hepatitis d | D019701 | — | — | — | 1 | 2 | — | 1 | 4 |
| Hepatitis d | D003699 | EFO_0007304 | — | — | 1 | 2 | — | 1 | 4 |
| Essential thrombocythemia | D013920 | — | D47.3 | 1 | 1 | 1 | — | — | 3 |
| Polycythemia vera | D011087 | — | D45 | 1 | 1 | 1 | — | — | 3 |
| Thrombocytosis | D013922 | — | D75.83 | 1 | 1 | 1 | — | — | 3 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | 1 | 1 | — | — | 3 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 1 | 3 | — | — | 3 |
| Leukemia | D007938 | — | C95 | — | — | 2 | — | — | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | 1 | 1 | — | — | — | 2 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | 1 | 1 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Margins of excision | D000072662 | — | — | — | 1 | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Treatment failure | D017211 | — | — | — | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Papillomavirus infections | D030361 | — | — | 1 | — | — | — | — | 1 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Interferon alfa-2a |
| INN | — |
| Description | Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be used alone. It is given by injection under the skin.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | 120608 |
| ChEMBL ID | CHEMBL2108508 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00008 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 45 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30,717 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use